Posted by Michael Wonder on 10 Feb 2026
FGFR4 inhibitor irpagratinib granted FDA fast track designation for HCC patients
10 February 2026 - Abbisko Therapeutics announced that the US FDA has granted fast track designation to irpagratinib (ABSK-011), a highly selective small molecule FGFR4 inhibitor independently developed by Abbisko Therapeutics, for the treatment of patients with hepatocellular carcinoma with FGF19 overexpression who have been previously treated with immune checkpoint inhibitors and multi-targeted kinase inhibitor therapies.
